Verification evidence is still being completed.
PDF / print export
Calluna Pharma AS
Oslo, Norway
- Verified lead
- Mark Gaffney
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- First-in-Class Antibody Therapeutics, Fibrosis, and Inflammatory Disease
- Review cycle
- 24 April 2026
- Full address
- Gaustadalleen 21, N-0349 Oslo, Norway (Oslo Science Park)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Calluna Pharma press release confirming Mark Gaffney as Chief Executive Officer.
- Editorial note
- Oslo fibrosis and inflammation biotech with a named CEO, Phase 1 completion on lead antibody CAL101, and Forbion backing after the 2023 Oxitope and Arxx merger.
First-in-Class Antibody Therapeutics, Fibrosis, and Inflammatory Disease
Public CEO disclosure via press release, Phase 1 completion of CAL101, Forbion-backed portfolio listing
Oslo fibrosis and inflammation biotech with a named CEO, Phase 1 completion on lead antibody CAL101, and Forbion backing after the 2023 Oxitope and Arxx merger.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Oslo, Norway
Calluna Pharma AS
First-in-Class Antibody Therapeutics, Fibrosis, and Inflammatory Disease · Clinical-stage antibody development
Oslo fibrosis and inflammation biotech with a named CEO, Phase 1 completion on lead antibody CAL101, and Forbion backing after the 2023 Oxitope and Arxx merger.
- Lead
- Mark Gaffney (verified ↗)
- Address
- Gaustadalleen 21, N-0349 Oslo, Norway (Oslo Science Park) (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage antibody development
- Capabilities
- First-in-Class Antibody Discovery · CAL101 Phase 1 Complete · Fibrotic Disease Focus
- Founded
- 2024
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Mark Gaffney
Chief Executive Officer
Full addressGaustadalleen 21, N-0349 Oslo, Norway (Oslo Science Park)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Calluna Pharma contact page listing Gaustadalleen 21, Oslo Science Park.
Open sourceClinical-stage antibody development
Oslo, Norway. First-in-Class Antibody Therapeutics, Fibrosis, and Inflammatory Disease. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and EMA for clinical oversight
Public CEO disclosure via press release, Phase 1 completion of CAL101, Forbion-backed portfolio listing
First-in-Class Antibody Therapeutics, Fibrosis, and Inflammatory Disease
Oslo fibrosis and inflammation biotech with a named CEO, Phase 1 completion on lead antibody CAL101, and Forbion backing after the 2023 Oxitope and Arxx merger.
Editorial note
Calluna Pharma was formed in 2023 from the merger of Oxitope Pharma and Arxx Therapeutics, is backed by Forbion, and has a documented Phase 1 completion for CAL101 alongside a named CEO since 2024.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
First-in-Class Antibody Discovery
CAL101 Phase 1 Complete
Fibrotic Disease Focus
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody discovery platform
Clinical trial operations
Partner CDMO biologics supply
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Calluna Pharma AS located?
- Calluna Pharma AS operates from Gaustadalleen 21, N-0349 Oslo, Norway (Oslo Science Park), Oslo, Norway.
- Who runs Calluna Pharma AS?
- Calluna Pharma AS is led by Mark Gaffney, Chief Executive Officer. Verified 24 Apr 2026.
- What does Calluna Pharma AS do?
- Oslo fibrosis and inflammation biotech with a named CEO, Phase 1 completion on lead antibody CAL101, and Forbion backing after the 2023 Oxitope and Arxx merger. Core capabilities: First-in-Class Antibody Discovery, CAL101 Phase 1 Complete, Fibrotic Disease Focus.
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.